Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
Nicholas D JamesFiona C InglebyNoel W ClarkeClaire L AmosGerhardt AttardChristopher D BrawleySimon ChowdhuryWilliam R CrossDavid P DearnaleyDuncan C GilbertSilke Gillessen SommerRobert J JonesRuth E LangleyArchie MacnairZafar I MalikMalcolm D MasonDavid J MathesonRobin MillmanChris C ParkerHannah L RushJ Martin RussellCarly AuAlastair W S RitchieRicardo Pereira MestreImtiaz AhmedAlison Jane BirtleSusannah J BrockPrantik DasVictoria A FordEmma K GrayRobert J HughesCaroline B ManettaDuncan B McLarenAshok D NikapotaJoe M O'SullivanCarla PernaClive PeedellAndrew S ProtheroeSanthanam SundarJacob S TanguayShaun P TolanJohn WagstaffJan B WallaceJames P WylieAnjali ZarkarMahesh K B ParmarMatthew Robert SydesPublished in: JNCI cancer spectrum (2022)
There is robust evidence that SOC plus docetaxel improved FFS and PFS (previously shown to increase quality-adjusted life-years), without excess late toxicity, which did not translate into benefit for longer-term outcomes. This may influence patient management in individual cases.